The Spitterati and Trickle-Down Genomics
By Marcy Darnovsky,
Mother Jones blog
| 11. 03. 2008
Just before the world's financial system hit the skids, the New Yorker's Talk of the Town and the New York Times' Sunday Styles section both featured lengthy accounts of a celebrity "spit party," at which notables in cocktail attire ejected their saliva into test tubes. The chic gala, hosted by media moguls Barry Diller, Rupert Murdoch, and Harvey Weinstein, was the latest episode of a remarkable publicity push by 23andMe, the start-up biotech firm whose mission is "to be the world's trusted source of personal genetic information."
The Google-backed company launched its celebrity strategy this past January, when it distributed a thousand free spit kits at the elite World Economic Forum in Davos, Switzerland. But the genomes of the rich and famous were just the first step. Early this fall, 23andMe announced that it's slashing its prices to Christmas-stocking levels, in a bid to make DNA tests this year's high-tech must-have.
This is shrewd promotion. Though the spreading economic gloom may put a ding in sales of $399 spit kits, 23andMe remains on a media roll. The company has...
Related Articles
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...